Musculus senhousei peptides (MSPs) regulate alcohol-induced dysfunction of gut microbiota and intestinal barrier, alleviating hepatic oxidative stress, inflammation, apoptosis, and subsequently liver injury.

The aim of this study was to investigate the effects of bergamot polysaccharide (BP) and Laoxianghuang polysaccharides (LPs, fermented bergamot) on the microbiome and metabolome during the in vitro fermentation of gut microbiota from patients with hyperlipidemia. Results indicated that both BP and LPs were able to increase the production of acetic acid, propionic acid, and butyric acid. However, only LPs could decrease the content of isobutyric acid and isovaleric acid, which are detrimental to gut health. A 16S rRNA analysis showed that both BP and LPs could reduce the proportion of Fusobacterium, whereas they increased the Bacteroides content in hyperlipidemia. Untargeted UPLC-MS/MS metabolomic profiling found six bio-markers that were significantly changed after BP and LPs intervention, and four of the down-regulated metabolites were long-chain fatty acids associated with vascular diseases. These findings provide new evidence that BP and LPs have the potential to regulate imbalances in the gut microbiota in patients with hyperlipidemia and ameliorate its metabolic abnormalities.

The current study aimed to assess the anti-diabetic effects and potential mechanisms of two Sargassum fusiform polysaccharide fractions (SFPs, named SFP-1 and SFP-2). The carbohydrate-loading experiment revealed that SFP-2 could control postprandial hyperglycemia by inhibiting the activity of digestive enzymes in rats. The analysis of diabetic symptoms and serum profiles indicated that SFPs could mitigate diabetes accompanied by dyslipidemia, and SFP-2 showed better regulatory effects on body weight, food intake and the levels of total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C) and free fatty acid (FFA) in diabetic rats. Intestinal bacterial analysis showed that SFP treatment could reshape the gut flora of diabetic rats, and SFP-2 possessed a greater regulatory effect on the growth of Lactobacillus and Blautia than SFP-1. RT-qPCR analysis revealed that SFPs could regulate the genes involved in the absorption and utilization of blood glucose, hepatic glucose production and lipid metabolism, and the effects of SFP-2 on the relative expressions of Protein kinase B (Akt), Glucose-6-phosphatase (G-6-Pase), Glucose transporter 2 (GLUT2), AMP-activated protein kinase-α (AMPKα), Peroxisome proliferator-activated receptor γ (PPARγ) and Cholesterol 7-alpha hydroxylase (CYP7A1) were greater than SFP-1. All above results indicated that SFPs could be exploited as functional foods or pharmaceutical supplements for the treatment of diabetes and its complications.